Close
Smartlab Europe
Inizio Ignite

Press Releases

Sharp Announces $650K Investment to Enhances IRT Solution

Sharp has announced a $650,000 investment into enhancing its Interactive Response Technology (IRT) solution. Sharp’s IRT solution is used to manage patient interactions and drug supplies during clinical trials and perform a range of functions for sponsors, drug depots...

EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with CD30+ Stage IV Hodgkin Lymphoma

Takeda Pharmaceutical Co. announced that the EC extended the current marketing authorization of ADCETRIS to include treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine). ...

Lonza Launches New Reliable, Robust and Customizable Pooled Donor Suspension Hepatocytes

Lonza announces the launch of DonorPlex Hepatocytes, a new line of high-quality cryopreserved pooled donor suspension hepatocytes, which are the first of their kind to be produced using Lonza’s novel patented manufacturing process. Researchers within DMPK...

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist...

Silgan Dispensing’s Iridya Addresses Unmet Patient Needs in Ophthalmic Drug Delivery Market

Silgan Dispensing, a global leader in the design, development and manufacturing of highly engineered pumps and sprayers in the pharmaceutical, home and beauty markets, will highlight its newest ophthalmic dispensing solution, Iridya™, at this year’s Pharmapack, Europe’s dedicated Pharmaceutical...

Marken To Build New GMP-Compliant Facility In Philadelphia

Marken announced the expansion of its facilities in Philadelphia to include more space for logistics operations as well as a new GMP-compliant storage and distribution center to meet the growing demand for services in the area. ...

Pexidartinib Granted Priority Review by FDA for Treatment of Tenosynovial Giant Cell Tumor

Daiichi Sankyo Company, Limited announced that the U.S. FDA has accepted a New Drug Application (NDA) and granted Priority Review for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Which...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »